✦ LIBER ✦

PND7 AN ANALYTICAL MODEL TO PREDICT THE COST-EFFECTIVENESS OF LONG-TERM ESZOPICLONE FOR THE TREATMENT OF PRIMARY INSOMNIA

✍ Scribed by SJ Snedecor; MF Botteman; K Schaefer; N Barry; R Rubens; AS Pickard

Book ID: 119596206
Publisher: John Wiley and Sons
Year: 2007
Tongue: English
Weight: 94 KB
Volume: 10
Category: Article
ISSN: 1098-3015
DOI: 10.1016/s1098-3015(10)65345-4

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Cost Effectiveness of Long-Term Treatmen

Cost Effectiveness of Long-Term Treatment with Eszopiclone for Primary Insomnia in Adults

✍ Botteman, Marc F; Ozminkowski, Ron J; Wang, Shaohung; Pashos, Chris L; Schaefer, 📂 Article 📅 2007 🏛 Adis International Limited (now part of Wolters Kl 🌐 English ⚖ 157 KB

PND28 COMPARISON OF FOUR PREFERENCE-BASE

PND28 COMPARISON OF FOUR PREFERENCE-BASED SF-36/SF-I2 ALGORITHMS TO EVALUATE THE COST-EFFECTIVENESS OF TREATMENT FOR PRIMARY INSOMNIA WITH ESZOPICLONE

✍ SJ Snedecor; MF Botteman; K Schaefer; N Barry; R Rubens; AS Pickard 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 64 KB

A model of the long-term cost effectiven

A model of the long-term cost effectiveness of scheduled maintenance treatment with infliximab for moderate-to-severe ulcerative colitis

✍ H. H. TSAI; Y. S. PUNEKAR; J. MORRIS; P. FORTUN 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 471 KB

Estimating the Long-Term Cost-Effectiven

Estimating the Long-Term Cost-Effectiveness of Exenatide in the United States: An Adjunctive Treatment for Type 2 Diabetes Mellitus

✍ Michael E. Minshall; Alan K. Oglesby; Matthew E. Wintle; William J. Valentine; S 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 303 KB

PMS47 The Long Term Cost-Effectiveness o

PMS47 The Long Term Cost-Effectiveness of Golimumab for the Treatment of Severe, Active Ankylosing Spondylitis in Adults Who Have Responded Inadequately to Conventional Therapy

✍ J. Farrell; N. Muszbek; O. Sheppard; M. Chaudhary; H. Naci; S. Kachroo 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 61 KB

A Model of the Cost Effectiveness of Inf

A Model of the Cost Effectiveness of Infliximab for the Treatment of Severely Active Ulcerative Colitis, in Children and Adolescents Aged 6 to 17 Years, Who Have Had an Inadequate Response to Conventional Therapy

✍ Farrell, J.; Jiang, Y.; Chaudhary, M.A.; Sheppard, O.; Gathany, T.; Fan, T. 📂 Article 📅 2013 🏛 John Wiley and Sons 🌐 English ⚖ 58 KB